Tuesday, November 24, 2020
Home Tags Oncology

Tag: oncology

Incorporating Genomics into Lymphoma Classification Can Improve Care | Targeted Oncology

The incorporation of genomics into the classification and treatment decision-making process for lymphomas is possible; however, many obstacles have prevented the incorporation of sequencing...

Big Data–Based Tools Support Cancer Clinical Decision-Making | Targeted Oncology

Clinicians are increasingly looking to big data and electronic medical records (EMR) data integration tools in support of clinical decision-making questions and processes for...

FDA Grants Priority Review to Lonca in R/R Diffuse Large B-Cell...

The FDA has accepted a Biologic License Application (BLA) for loncastuximab tesirine (Lonca) as treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma...

CAR T-Cell Therapy Continues to Spark Interest for Treatment of Patients...

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) continue to show benefit with chimeric antigen receptor (CAR) T-cell therapy, which has led to a...

Novel Small Molecule +/- Pembrolizumab Induces Responses in Various Solid Tumors...

The oral small molecule FLX475 demonstrated promise when administered either alone or in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) in multiple solid...

Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the...

Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer Details Category: Antibodies Published on...

FDA Postpones Review of BLA for Liso-Cel in R/R Large B-Cell...

The FDA will not complete its review of the Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy...

City of Hope’s Precision Oncology Tumor Board Able to Identify Patients...

DUARTE, Calif.--(BUSINESS WIRE)--City of Hope has compiled a premier precision oncology tumor board that systematically looks...

Biomarker for Immune Response Identified in Relapsed/Refractory DLBCL | Targeted Oncology

In patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), findings from the ongoing phase 2 SPiReL study (NCT03349450) demonstrated that certain gene...

Meeting Agenda Focuses on Increased Applications of Cellular Therapies in Hematologic...

There has been a surge in treatment advancements for multiple myeloma that have improved outcomes for patients in the front- and later-line disease settings,...
20,764FansLike
2,452FollowersFollow
16,600SubscribersSubscribe

EDITOR PICKS